Get the Stockscreener App
3.7516
2.17%
0.0716
Nexalin Technology Inc stock is traded at $3.7516, with a volume of 398.17K.
It is up +2.17% in the last 24 hours and up +17.87% over the past month.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$3.68
Open:
$3.65
24h Volume:
398.17K
Relative Volume:
0.55
Market Cap:
$48.96M
Revenue:
$128.60K
Net Income/Loss:
$-4.60M
P/E Ratio:
-5.9549
EPS:
-0.63
Net Cash Flow:
$-3.74M
1W Performance:
+28.77%
1M Performance:
+17.87%
6M Performance:
+261.54%
1Y Performance:
+1,079%
1-Day Range:
$3.42
$3.78
1-Week Range:
$2.70
$3.87
52-Week Range:
$0.2528
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
3.7516 | 48.96M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
128.84 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.35 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
391.73 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.81 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.04 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Nexalin Technology Inc Stock (NXL) Latest News
Nexalin Technology announces effective registration statement - Investing.com
Nexalin technology's chief medical officer buys $3,100 in shares - MSN
Nexalin Technology Inc (NXL) Stock: A Year of Highs and Lows - The InvestChronicle
Nexalin Technology Inc (NXL) Becoming More Attractive for Investors - Knox Daily
Nexalin Technology announces publication of study of DIFS technology - MSN
Can you still get a good price for Nexalin Technology Inc (NXL) Shares at this point? - US Post News
Nexalin technology's chief medical officer buys $2,980 in common stock - MSN
Quoin Pharmaceuticals launches Netherton awareness campaign - MSN
Nexalin’s Breakthrough DIFS™ Neurostimulation Device - GlobeNewswire
Nexalin Technology, Inc. Reports Landmark Study Highlights Efficacy of DIFS™ Technology in Reducing Blood Pressure in Patients with Major Depressive Disorder - Nasdaq
Clinical Trial: New Depression Therapy Achieves Dual Brain and Heart Benefits - StockTitan
Reviewing Nexeon Medsystems (OTCMKTS:NXNN) and Nexalin Technology (NASDAQ:NXL) - Defense World
NXLNexalin Technology, Inc. Latest Stock News & Market Updates - StockTitan
Nexalin technology's chief medical officer buys $4,050 in stock - MSN
Nexalin technology's chief medical officer buys $4,050 in stock By Investing.com - Investing.com Australia
Nexalin technology's chief medical officer buys $7,700 in stock - MSN
Nexalin Technology (NASDAQ:NXL) vs. CeriBell (NASDAQ:CBLL) Head-To-Head Contrast - Defense World
Nexalin technology's chief medical officer buys $7,700 in stock By Investing.com - Investing.com Australia
Nexalin Technology, Inc. Invites Investors to Webinar on Advancements in Neurostimulation and Mental Health Solutions - Nasdaq
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23 - The Manila Times
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23 - The Bakersfield Californian
Nexalin Tech CEO to Showcase Revolutionary Brain Treatment Device in Exclusive Investor Webinar - StockTitan
Nexalin Technology CEO Mark White Issues Letter to - GlobeNewswire
Nexalin Technology CEO sends letter to shareholders - TipRanks
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025 - The Manila Times
Nexalin's Revolutionary DIFS Technology Shows 65% Success Rate in Depression Treatment - StockTitan
Head-To-Head Survey: IMRIS (OTCMKTS:IMRSQ) vs. Nexalin Technology (NASDAQ:NXL) - Defense World
Certain Common Stock of Nexalin Technology, Inc. are subject to a Lock-Up Agreement Ending on 2-JAN-2025. - Marketscreener.com
Certain Options of Nexalin Technology, Inc. are subject to a Lock-Up Agreement Ending on 2-JAN-2025. - Marketscreener.com
Nexalin Technology (NASDAQ:NXL) Shares Up 5.5% – Here’s What Happened - Defense World
How Do Things Look For Nexalin Technology Inc (NASDAQ: NXL) In The Short-Term? - Stocks Register
Nexalin Technology, Inc. Launches Phase 1 of AI-Driven Virtual Clinic to Enhance Mental Health Treatment - Nasdaq
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic - GlobeNewswire
Nexalin Technology, Inc. Completes Phase 1 of Its Innovative Virtual Clinic - Marketscreener.com
Nexalin Launches AI-Powered Virtual Clinic Platform for Remote Mental Health Treatment Trials - StockTitan
Target Corp (TGT-N) QuotePress Release - The Globe and Mail
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Maxim Group Reaffirms Hold Rating for Nexalin Technology (NASDAQ:NXL) - Defense World
Nexalin Technology’s Strong Financial Position: No Defaults on Senior Securities - MSN
Nexalin Technology downgraded to Hold from Buy at Maxim - MSN
Maxim Group Downgrades Nexalin Technology (NXL) - MSN
Nexalin Technology Stock Soars to All-Time High of $4.4 Amidst Stunning Growth - Investing.com Canada
Nexalin Technology (NASDAQ:NXL) and ENDRA Life Sciences (NASDAQ:NDRA) Head-To-Head Survey - Defense World
Nexalin Technology, Inc. (NASDAQ:NXL) Short Interest Update - MarketBeat
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nexalin Technology Inc Stock (NXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
2.98 |
1,000 |
2,980 |
154,793 |
| Owens David | Chief Medical Officer |
Jan 28 '25 |
Buy |
2.70 |
1,500 |
4,050 |
153,793 |
| Owens David | Chief Medical Officer |
Jan 13 '25 |
Buy |
2.50 |
2,000 |
5,000 |
151,293 |
| Owens David | Chief Medical Officer |
Jan 23 '25 |
Buy |
2.70 |
1,000 |
2,700 |
152,293 |
| Owens David | Chief Medical Officer |
Oct 28 '24 |
Buy |
2.19 |
500 |
1,095 |
148,293 |
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):